Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionPlace of product in therapyDisease description

Diagnosis

11 evidence topics · 15 sources

Summary: histologic diagnosis, grading, and molecular testing

ACC is diagnosed by biopsy with histology and immunohistochemistry, after CT or MRI to define local extent and stage. Grading is based on the solid component: the Perzin/Szanto system uses a >30% solid cutoff, the Spiro system >50%, the van Weert system the presence of any solid component, and the WHO notes a worse course when the solid component exceeds one third of the tumor. Interobserver agreement was moderate for the Perzin/Szanto (kappa 0.393) and Spiro (kappa 0.433) systems and 0.990 for the van Weert system. High-grade transformation is distinguished from solid ACC by nuclear enlargement and irregularity, higher mitotic counts, and loss of biphasic differentiation.

Molecular testing supports diagnosis and subtyping. MYB::NFIB FISH had 42.9% sensitivity and 100% specificity, and a MYB RNA in situ hybridization model had 93.2% sensitivity and 97.1% specificity in 79 cases. ACC-I and ACC-II can be assigned with MYC and p63 immunohistochemistry (AUROC 0.99). NOTCH pathway activation can be identified by genomic sequencing or NICD1 immunohistochemistry.

Histologic grading: Perzin/Szanto, Spiro, and van Weert systems